Physician profile
Ednan Sheikh
NPI 1013128016
$7,828.82
in general payments reported to CMS, 2019-2025
30 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,673 · 2020: $450 · 2021: $2,690 · 2022: $536 · 2023: $534 · 2024: $1,462 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,787 · Travel and Lodging: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,787.09 |
| Travel and Lodging | $692.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,409.91 | 2019-2025 | Relistor |
| Surgentec | $1,307.40 | 2021 | |
| Medtronic Vascular, INC. | $1,251.52 | 2019 | |
| Redhill Biopharma INC. | $1,160.16 | 2020-2022 | |
| Boston Scientific Corporation | $1,090.25 | 2019-2024 | Intracept, Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $587.14 | 2019-2025 | Xtampza |
| Biodelivery Sciences International, INC. | $160.11 | 2019-2021 | |
| Allergan, INC. | $116.02 | 2021-2022 | |
| Si-Bone, INC. | $112.04 | 2022-2024 | |
| Medtronic, INC. | $86.12 | 2023-2025 | Invos, Intellis Adaptivestim, Inceptiv |
| Astrazeneca Pharmaceuticals LP | $82.52 | 2019 | |
| Shionogi INC | $67.94 | 2019 | |
| Nalu Medical, INC. | $41.65 | 2025 | Nalu Neurostimulation System |
| Glaxosmithkline, LLC. | $39.97 | 2019-2021 | |
| Relievant Medsystems, INC. | $39.10 | 2023 | Intracept |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $31.88 | 2022-2023 | |
| Azurity Pharmaceuticals, INC. | $31.76 | 2023 | Horizant |
| Protega Pharmaceutials INC | $28.92 | 2023 | Roxybond |
| Abbott Laboratories | $21.72 | 2021 | |
| Foundation Fusion Solutions, LLC | $18.50 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $17.81 | 2025 | |
| Valinor Pharma, LLC | $16.79 | 2025 | Movantik |
| Biotronik Nro, INC. | $16.46 | 2025 | Prospera |
| Electronic Waveform Lab, INC. | $14.65 | 2025 | |
| Abbvie INC. | $14.05 | 2023 | Botox |
| Daiichi Sankyo INC. | $13.67 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.57 | 2019 | |
| Ibsa Pharma INC. | $12.73 | 2023 | Tirosint, Licart |
| Biocompatibles, INC. | $12.53 | 2019 | |
| Almatica Pharma LLC | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ednan Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.